SERUM SOLUBLE CD25 IN HEPATOCELLULAR CARCINOMA, SHALL WE BE ABLE TO CHANGE THE NATURAL HISTORY?
DOI:
https://doi.org/10.11603/ijmmr.2413-6077.2017.2.8009Ключові слова:
hepatocellular carcinoma, soluble CD25, alfa fetoprotein.Анотація
Background. Although hepatocellular carcinoma (HCC) is one of the most common malignancy related mortality worldwide, it can be curable if detected in early stages. Emergence of a new marker that can early detect HCC could help in early treatment and therefore ameliorate the outcome.
Objective. The aim of the research is to evaluate the performance of serum soluble CD25 (sCD25) in the prediction of early HCC and compare it to α-fetoprotein (AFP).
Methods. Serum levels of sCD25 and AFP were measured in three groups of population; HCC group (40 patients), cirrhosis without HCC control group (20 patients) and healthy control group (20 patients). HCC group contained 20 early and 20 late stage patients according to Barcelona Clinic Liver Cancer (BCLC) staging system (stage 0/A and B-D respectively). Levels of both biomarkers were compared in all groups. Predictive yield of both biomarkers for early HCC was evaluated using ROC curve analysis.
Results. Level of sCD25 was significantly higher in patients with HCC than in both cirrhotic controls and healthy controls (P<0.0001and 0.013 respectively). For prediction of early HCC in patients with cirrhosis, the optimal sCD25 cut-off level was 7.15 ng/ml with sensitivity and specificity of 90% and 60% respectively (AUC=0.717; P=0.019) while sensitivity and specificity of AFP were 70% and 85% respectively at a cut-off value of 9.85 ng/ml (AUC=0.781; P=0.002) in the same settings.
Conclusion. sCD25 seems to be a reliable biomarker for early detection of HCC and therefore could enhance the outcome.
Посилання
El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142:1264–1273. e1. PMID: 22537432 DOI: 10.1053/j.gastro.2011.12.061.
El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365:1118–1127.
Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancerburden: Globocan 2000. Int J Cancer. 2001;94:153–6.
Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907–1917.
El-Serag HB, Kramer JR, Chen GJ, Duan Z, Richardson PA and Davila JA. Effectiveness of AFP and ultrasound tests on hepa¬tocellular carcinoma mortality in HCV-infected patients in the USA. Gut. 2011;60:992–997.
Benowitz S. Liver cancer biomarkers struggling to succeed. J Natl Cancer Inst. 2007;99:590–591.
Sherman M. Current status of α-fetoprotein testing. GastroenterolHepatol (NY). 2011;7:113–114.
Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020–1022. PMID: 21374666 DOI: 10.1002/hep.24199.
Cao M, Cabrera R, Xu Y, et al. Hepatocellular carcinoma cell supernatantsincrease expansion and function of CD4(+)CD25(+) regulatoryT cells. Lab Invest. 2007;87:582–90.
Foss FM. Immunologic mechanisms of antitumor activity. SeminOncol. 2002;29:5–11.
Cabrera R, Ararat M, Cao M, et al. Hepatocellular carcinoma immunopathogenesis:clinical evidence for global T cell defects and an immunomodulatory role for soluble CD25 (sCD25). Dig Dis Sci. 2010;55:484–95.
Cabrena R, Fitian A, Ararat M, et al. Serum levels of soluble CD25 as a marker for hepatocellular carcinoma. Oncology Letters. 2012;4:840–846.
Nakamoto Y, Guidotti LG, Kuhlen CV, Fowler P and Chisari FV. Immune pathogenesis of hepatocellular carcinoma. J Exp Med. 1998;188:341–350.
Cacalano NA and Johnston JA: Interleukin-2 signaling and inherited immunodeficiency. Am J Hum Genet . 1999;65:287–293.
Hoechst B, Ormandy LA, Ballmaier M, et al. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology. 2008;135:234–243.
Arun B, Curti BD, Longo DL, et al. Elevations in serum soluble interleukin-2 receptor levels predict relapse in patients with hairy cell leukemia. Cancer J Sci Am 6. 2000;21–24.
Forner A, Reig ME, de Lope CR, et al. Current strategy for staging and treatment: the BCLC update and future prospects. Semin. Liver Dis. 2010;30 (01):61–74.
Choi JY, Lee JM, Sirlin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects. Radiology. 2014;272(3):635–54.
Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60(8):646–9.
Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127 Suppl 1:S35-S50.
Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:1245–1255. PMID: 22353262 DOI: 10.1016/S0140-6736(11)61347-0.
Marrero JA. Current Treatment Approaches in HCC. Clin Adv Hematol Oncol. 2013;11 Suppl 5:15–18.
